Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of Trametinib and Nab-paclitaxel in Patients With Melanoma

NCT02300935 is registered in ClinicalTrials.gov with SCRI Development Innovations, LLC as lead sponsor.

NCT NCT02300935
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02300935 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of Trametinib and Nab-paclitaxel in Patients With Melanoma
Lead sponsor
SCRI Development Innovations, LLC
Phase
Phase 1
Overall status
Withdrawn
Start date
December 31, 2015
Completion date
January 20, 2016
Enrollment
0 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma